Shattuck lecture - Diversity of the immune repertoire and immunoregulation

New England Journal of Medicine

Volumn 348, Issue 11, 2003, Pages 1017-1026

  Schwartz, Robert S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE DISEASE; DISEASE ASSOCIATION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOLOGY; IMMUNOREGULATION; PRIORITY JOURNAL;

EID: 0037434896     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMsa022766     Document Type: Article

References (103)

1. Health, United States, 2002: with chartbook on trends in the health of Americans. Washington, D.C.: Government Printing Office, 2002.
2. Ehrlich P. On immunity with special reference to cell life. Proc R Soc Lond 1900;66:424-48.
3. Cambrosio A, Jacobi D, Keating P. Ehrlich's "beautiful pictures" and the controversial beginnings of immunological imagery. Isis 1993;84:662-99.
4. Silverstein AM. Paul Ehrlich's receptor immunology: the magnificent obsession. San Diego, Calif.: Academic Press, 2002.
5. Jerne NK. The natural-selection theory of antibody formation. Proc Natl Acad Sci U S A 1955;41:849-57.
6. Burnet FM. A modification of Jerne's theory of antibody production using the concept of clonal selection. Aust J Sci 1957;20:67-9.
7. Talmage DW. Immunological specificity: unique combinations of selected natural globulins provide an alternative to the classical concept. Science 1959;129:1643-8.
8. Lederberg J. Genes and antibodies. Science 1959;129:1649-53.
9. Schwartz RS. Jumping genes and the immunoglobulin V gene system. N Engl J Med 1995;333:42-4.
10. Matsuda F, Honjo T. Organization of the human immunoglobulin heavy-chain locus. Adv Immunol 1996;62:1-29.
11. Schwartz RS. Jumping genes. N Engl J Med 1995;332:941-4.
12. Oettinger MA, Schatz DG, Gorka C, Baltimore D. RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. Science 1990;248:1517-23.
13. Bassing CH, Swat W, Alt FW. The mechanism and regulation of chromosomal V(D)J recombination. Cell 2002;109:Suppl:S45-S55.
14. Kabat EA. Origins of antibody complementarity and specificity-hypervariable regions and the minigene hypothesis. J Immunol 1980;125:961-9.
15. Schwartz RS, Stollar BD. Heavy-chain directed B-cell maturation: continuous clonal selection beginning at the pre-B cell stage. Immunol Today 1994;15:27-32.
16. Le Campion A, Bourgeois C, Lambolez F, et al. Naive T cells proliferate strongly in neonatal mice in response to self-peptide/ self-MHC complexes. Proc Natl Acad Sci U S A 2002;99:4538-43.
17. Stefanova I, Dorfman JR, Germain RN. Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature 2002;420:429-34.
18. Stewart AK, Schwartz RS. Immunoglobulin V regions and the B cell. Blood 1994;83: 1717-30.
19. Blanden RV, Steele EJ. A unifying hypothesis for the molecular mechanism of somatic mutation and gene conversion in rearranged immunoglobulin variable genes. Immunol Cell Biol 1998;76:288-93.
20. Kelsoe G. The germinal center: a crucible for lymphocyte selection. Semin Immunol 1996;8:179-84.
21. Arakawa H, Hauschild J, Buerstedde JM. Requirement of the activation-induced deaminase (AID) gene for immunoglobulin gene conversion. Science 2002;295:1301-6.
22. Fugmann SD, Schatz DG. Immunology: one AID to unite them all. Science 2002;295: 1244-5.
23. Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A. T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 1999;283:680-2.
24. Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 1998;395:82-6.
25. Tuosto L, Parolini I, Schroder S, Sargiacomo M, Lanzavecchia A, Viola A. Organization of plasma membrane functional rafts upon T cell activation. Eur J Immunol 2001; 31:345-9.
26. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001;106:255-8.
27. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecular machine for controlling T cell activation. Science 1999;285:221-7.
28. Khan AA, Bose C, Yam LS, Soloski MJ, Rupp F. Physiological regulation of the immunological synapse by agrin. Science 2001;292: 1681-6.
29. Shaw AS, Allen PM. Kissing cousins: immunological and neurological synapses. Nat Immunol 2001;2:575-6.
30. Chicz RM, Urban RG, Lane WS, et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 1992;358:764-8.
31. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC. Identification of self peptides bound to purified HLA-B27. Nature 1991;353:326-9.
32. Kropshofer H, Max H, Halder T, Kalbus M, Muller CA, Kalbacher H. Self-peptides from four HLA-DR alleles share hydrophobic anchor residues near the NH2-terminal including proline as a stop signal for trimming. J Immunol 1993;151:4732-42.
33. Klein J, Sato A. The HLA system. N Engl J Med 2000;343:782-6. [Erratum, N Engl J Med 2000;343:1504.]
34. Idem. The HLA system. N Engl J Med 2000;343:702-9.
35. Anderton SM, Wraith DC. Selection and fine-tuning of the autoimmune T-cell repertoire. Nat Rev Immunol 2002;2:487-98.
36. Anderton SM, Radu CG, Lowrey PA, Ward ES, Wraith DC. Negative selection during the peripheral immune response to antigen. J Exp Med 2001;193:1-11.
37. Margulies DH. TCR avidity: it's not how strong you make it, it's how you make it strong. Nat Immunol 2001;2:669-70.
38. Kyewski B, Derbinski J, Gotter J, Klein L. Promiscuous gene expression and central T-cell tolerance: more than meets the eye. Trends Immunol 2002;23:364-71.
39. Derbinski J, Schulte A, Kyewski B, Klein L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2001;2:1032-9.
40. Wong D, Phelps RG, Turner AN. The Goodpasture antigen is expressed in the human thymus. Kidney Int 2001;60:1777-83.
41. Ohashi PS. Immunology: exposing thy self. Science 2002;298:1348-9.
42. Nikolic-Zugic J, Bevan MJ. Role of selfpeptides in positively selecting the T-cell repertoire. Nature 1990;344:65-7.
43. Zuklys S, Balciunaite G, Agarwal A, Fasler-Kan E, Palmer E, Hollander GA. Normal thymic architecture and negative selection are associated with Aire expression, the gene defective in the autoimmune-polyen-docrinopathy-candidiasis-ectodermal dystrophy (APECED). J Immunol 2000;165:1976-83.
44. Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002;298:1395-401.
45. Gibson TJ, Ramu C, Gemund C, Aasland R. The APECED polyglandular autoimmune syndrome protein, AIRE-1, contains the SAND domain and is probably a transcription factor. Trends Biochem Sci 1998;23:242-4.
46. Bjorses P, Aaltonen J, Horelli-Kuitunen N, Yaspo ML, Peltonen L. Gene defect behind APECED: a new clue to autoimmunity. Hum Mol Genet 1998;7:1547-53.
47. Moudgil KD, Sercarz EE. The self-directed T cell repertoire: its creation and activation. Rev Immunogenet 2000;2:26-37.
48. Souroujon M, White-Scharf ME, Andre-Schwartz J, Gefter ML, Schwartz RS. Preferential autoantibody reactivity of the preimmune B cell repertoire in normal mice. J Immunol 1988;140:4173-9.
49. Dutoit V, Rubio-Godoy V, Pittet MJ, et al. Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-A peptide multimer(+) CD8(+) T cells in humans. J Exp Med 2002;196: 207-16.
50. Germain RN. The art of the probable: system control in the adaptive immune system. Science 2001;293:240-5.
51. Germain RN, Stefanova I, Dorfman J. Self-recognition and the regulation of CD4+ T cell survival. Adv Exp Med Biol 2002;512: 97-105.
52. Naparstek Y, Andre-Schwartz J, Manser T, et al. A single germline VH gene segment of normal A/J mice encodes autoantibodies characteristic of systemic lupus erythematosus. J Exp Med 1986;164:614-26.
53. Bach J-F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-20.
54. Bretscher PA, Cohn M. Minimal model for the mechanism of antibody induction and paralysis by antigen. Nature 1968;220:444-8.
55. Abbas AK, Williams ME, Burstein HJ, Chang TL, Bossu P, Lichtman AH. Activation and functions of CD4+ T-cell subsets. Immunol Rev 1991;123:5-22.
56. Lohoff M, Koch A, Rollinghoff M. Two signals are involved in polyclonal B-cell stimulation by T helper type 2 cells: a role for LFA-1 molecules and interleukin 4. Eur J Immunol 1992;22:599-602.
57. Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci U S A 1999;96:185-90.
58. Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001;2:203-9.
59. Schwartz RH. T cell anergy. Scientific American. August 1993:62-71.
60. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med 2001;344: 655-64.
61. Quaratino S, Duddy LP, Londei M. Fully competent dendritic cells as inducers of T cell anergy in autoimmunity. Proc Natl Acad Sci U S A 2000;97:10911-6.
62. Munder M, Bettelli E, Monney L, Slavik JM, Nicholson LB, Kuchroo VK. Reduced self-reactivity of an autoreactive T cell after activation with cross-reactive non-self-ligand. J Exp Med 2002;196:1151-62.
63. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611-8.
64. Rudd CE, Martin M, Schneider H. CTLA-4 negative signaling via lipid rafts: a new perspective. Sci STKE 2002;2002:PE18.
65. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997;7:445-50.
66. Najafian N, Sayegh MH. CTLA4-Ig: a novel immunosuppressive agent. Expert Opin Investig Drugs 2000;9:2147-57.
67. Rottman JB, Smith T, Tonra JR, et al. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol 2001;2:605-11.
68. Sperling AI, Bluestone JA. ICOS costimulation: it's not just for TH2 cells anymore. Nat Immunol 2001;2:573-4.
69. Bleesing JJ, Straus SE, Fleisher TA. Autoimmune lymphoproliferative syndrome: a human disorder of abnormal lymphocyte survival. Pediatr Clin North Am 2000;47:1291-310.
70. Gershon RK, Kondo K. Infectious immunological tolerance. Immunology 1971;21: 903-14.
71. Tung KSK, Smith S, Teuscher C, Cook C, Anderson RE. Murine autoimmune oophoritis, epididymoorchitis, and gastritis induced by day 3 thymectomy: immunopathology. Am J Pathol 1987;126:293-302.
72. Smith H, Sakamoto Y, Kasai K, Tung KSK. Effector and regulatory cells in autoimmune oophoritis elicited by neonatal thymectomy. J Immunol 1991;147:2928-33.
73. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001;2:816-22.
74. McHugh RS, Shevach EM, Thornton AM. Control of organ-specific autoimmunity by immunoregulatory CD4(+)CD25(+) T cells. Microbes Infect 2001;3:919-27.
75. Taams LS, Vukmanovic-Stejic M, Smith J, et al. Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells. Eur J Immunol 2002;32:1621-30.
76. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400.
77. Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 2001;182:58-67.
78. Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. J Exp Med 2002;196:247-53. [Errata, J Exp Med 2002; 196:559, 867.]
79. Sasaki T, Sasaki-Irie J, Penninger JM. New insights into the transmembrane protein tyrosine phosphatase CD45. Int J Biochem Cell Biol 2001;33:1041-6.
80. Penninger JM, Irie-Sasaki J, Sasaki T, Oliveira-dos-Santos AJ. CD45: new jobs for an old acquaintance. Nat Immunol 2001;2: 389-96.
81. Sandrin MS, Mouhtouris E, Vaughan HA, Warren HS, Parish CR. CD48 is a low affinity ligand for human CD2. J Immunol 1993;151: 4606-13.
82. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-55.
83. Silverstein AM. The lymphocyte in immunology: from James B. Murphy to James L. Gowans. Nat Immunol 2001;2:569-71.
84. Dameshek W, Schwartz RS. Leukemia and auto-immunization - some possible relationships. Blood 1959;14:1151-8.
85. Schwartz R, Stack J, Dameshek W. Effect of 6-mercaptopurine on antibody production. Proc Soc Exp Biol Med 1958;99:164-7.
86. André JA, Schwartz RS, Mitus WJ, Dameshek W. The morphologic responses of the lymphoid system to homografts. I. First and second set responses in normal rabbits. Blood 1962;19:313-48.
87. Dameshek W, Schwartz R. Treatment of certain "autoimmune" diseases with antimetabolites: a preliminary report. Trans Assoc Am Physicians 1960;73:113-27.
88. Meeker W, Condie R, Weiner D, Varco RL, Good RA. Prolongation of skin homograft survival in rabbits by 6-mercaptopurine. Proc Soc Exp Biol Med 1959;102:459-61.
89. Calne RY. The rejection of renal homografts: inhibition in dogs by 6-mercaptopurine. Lancet 1960;1:417-8.
90. Zukoski CF, Lee HM, Hume DM. The prolongation of functional survival of canine renal homografts by 6-mercaptopurine. Surg Forum 1960;11:470-2.
91. Murray JE, Merrill JP, Harrison JH, Wilson RE, Dammin GJ. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med 1963; 268:1315-23.
92. Schwartz R, Dameshek W. The treatment of autoimmune hemolytic anemia with 6-mercaptopurine and thioguanine. Blood 1962;19:483-500.
93. Patterson JF, Norton RA, Schwartz RS. Azathioprine treatment of ulcerative colitis, granulomatous colitis and regional enteritis. Am J Dig Dis 1971;16:327-32.
94. Dyer MJ. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 1999;26:Suppl 14: 52-7.
95. Johnson PW, Glennie MJ. Rituximab: mechanisms and applications. Br J Cancer 2001;85:1619-23.
96. Lipsky PE, van der Heijde DMFM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
97. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
98. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the longterm efficacy of infliximab in Crohn's disease. N Engl J Med 2002;348:601-8.
99. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-52.
100. Granstein RD. New treatments for psoriasis. N Engl J Med 2001;345:284-7.
101. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93. [Errata, N Engl J Med 2001;344:76,240.]
102. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
103. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002;346:1349-56.